Adding romidepsin to busulfan and fludarabine reduced incidence of relapse among patients receiving allogeneic stem cell transplant for aggressive T-cell malignancies, according to results of a phase 1/phase 2 study.
The three-drug combination also mitigated the poor outcomes of patients with measurable residual disease prior to transplant, with toxicities similar to busulfan and fludarabine alone, initial findings presented at ASH Annual Meeting and Exposition showed.
“Unlike patients with B-cell malignancies, those with T-cell malignancies have very limited therapies, particularly in